Senseonics - SENS STOCK NEWS

Sequel Med Tech and Senseonics have partnered to create the first Automated Insulin Delivery (AID) System compatible with a one-year continuous glucose monitor. The integration combines Sequel's twiist™ AID System with Senseonics' Eversense® 365, the world's first and only one-year CGM system.

Key highlights:

• Launch expected in Q3 2025
• System offers enhanced diabetes management tools
• twiist will be compatible with both Eversense 365 and Abbott's FreeStyle Libre 3 Plus sensor
• Eversense 365 received FDA iCGM clearance in September 2024

The collaboration aims to provide greater flexibility and personalization for people with type 1 diabetes. This integration marks a significant advancement in diabetes care, combining Senseonics' long-duration CGM technology with Sequel's state-of-the-art insulin delivery system to potentially improve glucose control and increase convenience for users.

Senseonics Holdings (NYSE: SENS) reported Q4 and full year 2024 financial results, highlighting significant achievements in their diabetes care technology. The company's Eversense® 365 CGM system received FDA approval and launched in the US, leading to a 56% increase in global patient base to approximately 6,000 patients.

Q4 2024 revenue reached $8.3 million with a net loss of $15.5 million ($0.02 per share). Full-year 2024 revenue was $22.5 million with a net loss of $78.6 million ($0.12 per share). December marked the highest monthly new patient shipments at approximately 600.

Key highlights include:

• Exceeded 2,400 annual US Eversense prescribers in 2024
• 81% of patients switched from competitive CGMs
• Completed CE Mark application for Eversense 365 in EU
• Executed restructuring with $10M target cost reduction for 2025

For 2025, Senseonics projects global net revenue of $34-38 million with gross margins between 25-30%.

Senseonics Holdings (NYSE: SENS) and Ascensia Diabetes Care have announced the integration of SweetSpot™ software with the Eversense® 365 Continuous Glucose Monitoring (CGM) System in the U.S. This integration enables endocrinology practices partnered with SweetSpot to enhance patient care through seamless data review from the world's first and only One Year CGM system.

SweetSpot's platform combines centralized diabetes device data management with clinical support services. Their virtual team of Certified Diabetes Care and Education Specialists performs monthly CGM data reviews and coordinates with healthcare providers on treatment plans. The integration allows for personalized support between appointments and helps ensure timely treatment adjustments.

The partnership aims to improve glycemic control while offering practices automated capture of reimbursable care events. Eversense 365, developed by Senseonics and distributed by Ascensia, provides one year of accurate monitoring with minimal interruptions as the only implantable CGM available.

Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring (CGM) systems for diabetes patients, has announced its participation in the TD Cowen 45th Annual Health Care Conference in Boston, MA.

The company will deliver a corporate overview and conduct one-on-one meetings during the conference on Tuesday, March 4, 2025, at 3:10 pm ET. Interested parties can access both live and recorded webcasts of the presentation through the 'Investor Relations' section of Senseonics' website at www.senseonics.com.

Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has scheduled its fourth quarter and full year 2024 earnings release for March 3, 2025, after market close.

The company will host a conference call at 4:30 P.M. Eastern Time on the same day to discuss the financial results. Investors can access the call by dialing 1-800-445-7795 (US/Canada) or 1-785-424-1699 (International) using passcode SENSQ4. A concurrent webcast will be available on the company's website under the Investor Relations section and will be archived for future reference.

Senseonics Holdings (NYSE: SENS) has submitted a CE Mark registration for its Eversense 365 CGM system, the world's first one-year continuous glucose monitoring system. The device, already FDA-approved and launched in the US in October 2024, could soon be commercialized across EU member countries through Ascensia Diabetes Care.

The Eversense 365 system offers significant advantages over traditional short-term CGMs, including: year-long duration, removable smart transmitter, trusted alerts with exceptional accuracy, comfortable silicone-based adhesives, and weekly calibration requirements. Following CE Mark approval, the company plans distribution in Germany, Italy, Spain, Poland, Switzerland, and Sweden.

The system is cleared in the US as an integrated CGM (iCGM) system, compatible with insulin pumps for automated insulin delivery (AID) systems, with ongoing partnership discussions with pump manufacturers.

Senseonics Holdings (NYSE: SENS) announced preliminary Q4 2024 revenue of $8.3 million and full-year revenue of $22.5 million. The company reported significant growth following the FDA approval and launch of Eversense® 365, their implantable continuous glucose monitoring system.

Key achievements include a 56% increase in global patient base to 6,000, reaching over 1,000 U.S. prescribers in 2024. Post-launch indicators show doubled Direct to Consumer leads in Q4, record-high monthly patient shipments of 600 in December, and a 49% increase in patients switching from competitors. The company maintained approximately $74.9 million in cash and equivalents as of December 31, 2024.

Senseonics canceled its planned Special Meeting for a reverse stock split, citing recent share price appreciation. The company expects positive revenue growth in 2025, with detailed guidance to be provided with full fiscal year 2024 results.

Senseonics Holdings (NYSE: SENS) reported strong early performance indicators for its Eversense 365 launch, which began shipping in November. Key highlights include: doubled Direct-to-Consumer leads in October and November compared to pre-launch months, highest new patient shipments since Ascensia partnership began, 42% increase in prescribing providers, and 69% increase in prescriptions from top prescribers.

The company maintains its target of 50% annual growth in patient installed base for 2024 and reiterates global net revenue guidance of approximately $22 million. One-third of Eversense 365 prescribers are first-time users, and patient switches from competitive CGMs have increased 47% since launch. The company plans a reverse stock split in January 2025 to enhance appeal to institutional investors.

Senseonics Holdings (NYSE American: SENS), a medical technology company specializing in long-term, implantable continuous glucose monitoring systems for diabetes patients, has announced its participation in two upcoming investor conferences in November. The company will present at the Stifel 2024 Healthcare Conference on November 19, delivering a corporate overview and holding one-on-one meetings, with a presentation scheduled for 9:10 am ET. Additionally, management will participate in the Canaccord Genuity Medtech, Diagnostics, and Digital Health & Services Forum on November 21, conducting one-on-one meetings. Both events will be accessible via webcast through the company's investor relations website.